New drug combo shows promise in fighting rare blood cancer
NCT ID NCT02896582
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tested a drug called obinutuzumab combined with chemotherapy (DHAP) and a stem cell transplant in 86 adults with mantle cell lymphoma, a rare blood cancer. After the transplant, patients received obinutuzumab as maintenance therapy to keep the cancer from coming back. The goal was to see if this approach could reduce cancer cells to undetectable levels in the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hopital Necker
Paris, 75743, France
-
CH Perpignan
Perpignan, 66046, France
-
CH d'Avignon
Avignon, 84902, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHRU Bretonneau
Tours, 37044, France
-
CHRU Lille - Hôpital Claude Huriez
Lille, 59037, France
-
CHU Limoges
Limoges, 87042, France
-
CHU Lyon Sud
Pierre-Bénite, 69130, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Pontchaillou
Rennes, 35033, France
-
CHU Robert Debré
Reims, 51092, France
-
CHU d'Amiens
Amiens, 80480, France
-
CHU d'Angers
Angers, 49000, France
-
CHU de Brabois
Vandœuvre-lès-Nancy, France
-
CHU de Caen
Caen, 14033, France
-
CHU de Clermont Ferrand
Clermont-Ferrand, 63000, France
-
CHU de Dijon - Hôpital le Bocage
Dijon, 21034, France
-
CHU de Grenoble
Grenoble, 38700, France
-
CHU de Haut Leveque
Pessac, 33604, France
-
CHU de Poitiers
Poitiers, 86021, France
-
CHU de Strasbourg
Strasbourg, 67091, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Annecy-Genevois
Pringy, 74374, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Gustave Roussy Cancer Campus
Villejuif, 94805, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hôpital Saint Louis
Paris, 75475, France
-
I.U.C.T Oncopole
Toulouse, 31100, France
-
Institut de Cancérologie de Loire
Saint-Priest-en-Jarez, 42271, France
Conditions
Explore the condition pages connected to this study.